Product news

Share this article:

Novo Nordisk discontinued its experimental AERx inhaler and took a charge of $260 million in 2007, saying the product offered little clinical benefit. “Pfizer's decision on Exubera prompted this,” Mads Krogsgaard Thomsen, Novo's chief scientific officer, in  said in a published report. “We have realized that the trend is for physicians to start treatment with something simple rather than a device that has to be loaded with insulin for each mealtime use.” A Novo spokeswoman said that a “significant number'” of 360 jobs at the company's Hayward, California site will be “affected.”

Three Rivers Pharmaceutical has finalized acquisition of the hepatitis C drug Infergen from Valeant Pharmaceuticals International. Valeant is receiving $91 million from Three Rivers for the procurement.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.